Michael Cheng, MD
Assistant Professor
Medicine
School of Medicine

from the UCLA David Geffen School of Medicine, where he graduated with Alpha Omega Alpha honors. He completed his residency in Internal Medicine at UCSF and his fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center. Prior to returning to UCSF, Dr. Cheng was an Assistant Professor at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Cheng strives to provide individualized, compassionate care with a focus on precision oncology, and continues to be inspired by the tangible and substantial patient benefit driven by research advances. Dr. Cheng sees patients at UCSF Health, and his clinic is located in the Bakar Precision Cancer Medicine Building on the UCSF Mission Bay campus.

• Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation.
  JCO precision oncology 2023 Cheng ML, Huang Y, Luong N, LoPiccolo J, Nishino M, Sholl LM, Chirieac LR, Santucci AD, Rabin MS, Jänne PA, Coker S, Diamond JR, Hilton J, Shapiro GI, French CA
• Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.
  JCO precision oncology 2022 Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, Liu D, Beltran H, Sholl LM, Nishino M, Jänne PA
• BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.
  Cancers 2022 Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, Das S, Apfel A, Xu K, Kozicki M, Ünsal-Kaçmaz K, Hammell A, Wang G, Ravindran P, …
• Lipid pneumonia associated with mineral oil use presenting as fluorine-18-fluorodeoxy-D-glucose-avid lung mass.
  JTCVS techniques 2022 Cheng ML, Thomas V, Vaz N, Hammer MM, Nishino M, Vargas SO, Khalil HA
• Report of the First International Symposium on NUT Carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ…
• A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.
  JTO clinical and research reports 2022 Schneider JL, Muzikansky A, Lin JJ, Krueger EA, Lennes IT, Jacobson JO, Cheng M, Heist RS, Piotrowska Z, Gainor JF, Shaw AT, Dagogo-Jack I
• Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC.
  JCO precision oncology 2021 Cheng ML, Milan MSD, Tamen RM, Bertram AA, Michael KS, Ricciuti B, Kehl KL, Awad MM, Sholl LM, Paweletz CP, Jänne PA
• SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM
• Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
  Genome medicine 2021 Tsui DWY, Cheng ML, Shady M, Yang JL, Stephens D, Won H, Srinivasan P, Huberman K, Meng F, Jing X, Patel J, Hasan M, Johnson I, Gedvilaite E, Houck-Loomis B, Socci ND, Selcuklu SD, Seshan VE, Zhang H,…
• Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
  Journal for immunotherapy of cancer 2021 Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M, Forshew T, Lydon C, Nishino M, Cheng M, Awad M
• Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC.
  JCO precision oncology 2021 Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, Jänne PA, Oxnard GR, Paweletz CP
• Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
  CA: a cancer journal for clinicians 2020 Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR
• Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs.
  JCO precision oncology 2020 Cheng ML, Donoghue MTA, Audenet F, Wong NC, Pietzak EJ, Bielski CM, Isharwal S, Iyer G, Funt S, Bagrodia A, Bajorin DF, Reuter VE, Eng J, Joseph G, Bourque C, Bromberg M, Ling L, Selcuklu SD, Arcila …
• Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis.
  JCO precision oncology 2020 Lee Y, Clark EW, Milan MSD, Champagne C, Michael KS, Awad MM, Barbie DA, Cheng ML, Kehl KL, Marcoux JP, Rabin MS, Rotow JK, Sands JM, Jänne PA, Oxnard GR
• Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML
• Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.
  Melanoma research 2020 Postow MA, Chasalow SD, Kuk D, Panageas KS, Cheng ML, Yuan J, Wolchok JD
• Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
  Lung cancer (Amsterdam, Netherlands) 2019 Sands JM, Nguyen T, Shivdasani P, Sacher AG, Cheng ML, Alden RS, Jänne PA, Kuo FC, Oxnard GR, Sholl LM
• Tumour lineage shapes BRCA-mediated phenotypes.
  Nature 2019 Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, …
• Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
  JAMA oncology 2019 Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, …
• The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
  Cancer cell 2018 Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K,…
• Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Cheng ML, Oxnard GR
• Clinical tumour sequencing for precision oncology: time for a universal strategy.
  Nature reviews. Cancer 2018 Cheng ML, Berger MF, Hyman DM, Solit DB
• Novel biomarkers in bladder cancer.
  Urologic oncology 2018 Cheng ML, Iyer G
• Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care.
  Annals of internal medicine 2018 Cheng ML, Solit DB
• The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot?
  Cancer epidemiology 2015 Cheng ML, Zhang L, Borok M, Chokunonga E, Dzamamala C, Korir A, Wabinga HR, Hiatt RA, Parkin DM, Van Loon K
• Beyond sipuleucel-T: immune approaches to treating prostate cancer.
  Current treatment options in oncology 2014 Cheng ML, Fong L
• Effects of RANKL-Targeted Therapy in Immunity and Cancer.
  Frontiers in oncology 2014 Cheng ML, Fong L
• Abiraterone acetate for the treatment of prostate cancer.
  Expert opinion on pharmacotherapy 2012 Ryan CJ, Cheng ML
• Coccidioidal endophthalmitis in immunocompetent person, California, USA.
  Emerging infectious diseases 2012 Cheng ML, Leibowitz M, Ha E